Encephalitis

5
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
3 programs
1
2
ChimeriVax-JE, Japanese Encephalitis vaccinePhase 3Vaccine1 trial
Japanese encephalitis chimeric virus vaccinePhase 3Vaccine1 trial
Live attenuated Japanese encephalitis virus, then ChimeriVax diluentPhase 21 trial
Active Trials
NCT00981175Completed202Est. Feb 2008
NCT00314132Completed2,004Est. Nov 2006
NCT01092507Completed300Est. Oct 2011
CSL Behring
CSL BehringIL - Bradley
1 program
1
Immunoglobulins, IntravenousPhase 31 trial
Active Trials
NCT02308982Completed18Est. Sep 2022
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
1
MVA-BN-WEVPhase 21 trial
Active Trials
NCT06899802Active Not Recruiting411Est. Mar 2027
Precision BioSciences
1 program
mNGS for pathogen detectionN/A1 trial
Active Trials
NCT02910037Completed214Est. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CSL BehringImmunoglobulins, Intravenous
SanofiJapanese encephalitis chimeric virus vaccine
SanofiChimeriVax-JE, Japanese Encephalitis vaccine
Bavarian NordicMVA-BN-WEV
SanofiLive attenuated Japanese encephalitis virus, then ChimeriVax diluent
Precision BioSciencesmNGS for pathogen detection

Clinical Trials (6)

Total enrollment: 3,149 patients across 6 trials

NCT02308982CSL BehringImmunoglobulins, Intravenous

Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis

Start: Jan 2016Est. completion: Sep 202218 patients
Phase 3Completed
NCT01092507SanofiJapanese encephalitis chimeric virus vaccine

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Start: Mar 2010Est. completion: Oct 2011300 patients
Phase 3Completed
NCT00314132SanofiChimeriVax-JE, Japanese Encephalitis vaccine

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Start: Oct 2005Est. completion: Nov 20062,004 patients
Phase 3Completed
NCT06899802Bavarian NordicMVA-BN-WEV

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Start: Mar 2025Est. completion: Mar 2027411 patients
Phase 2Active Not Recruiting
NCT00981175SanofiLive attenuated Japanese encephalitis virus, then ChimeriVax diluent

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Start: Apr 2003Est. completion: Feb 2008202 patients
Phase 2Completed
NCT02910037Precision BioSciencesmNGS for pathogen detection

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

Start: Jun 2016Est. completion: Jul 2017214 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space